- Home
- VRA vs IMAB Comparison
VRA vs IMAB Comparison
Compare VRA & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRA
- IMAB
- Stock Information
- Founded
- VRA 1982
- IMAB 2014
- Country
- VRA United States
- IMAB United States
- Employees
- VRA N/A
- IMAB N/A
- Industry
- VRA Apparel
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- VRA Consumer Discretionary
- IMAB Health Care
- Exchange
- VRA Nasdaq
- IMAB Nasdaq
- Market Cap
- VRA 102.9M
- IMAB 83.8M
- IPO Year
- VRA 2010
- IMAB 2020
- Fundamental
- Price
- VRA $3.78
- IMAB $1.07
- Analyst Decision
- VRA Strong Buy
- IMAB Strong Buy
- Analyst Count
- VRA 1
- IMAB 3
- Target Price
- VRA $5.50
- IMAB $8.00
- AVG Volume (30 Days)
- VRA 313.2K
- IMAB 682.1K
- Earning Date
- VRA 03-12-2025
- IMAB 03-13-2025
- Dividend Yield
- VRA N/A
- IMAB N/A
- EPS Growth
- VRA N/A
- IMAB N/A
- EPS
- VRA N/A
- IMAB N/A
- Revenue
- VRA $405,268,000.00
- IMAB $3,313,984.00
- Revenue This Year
- VRA N/A
- IMAB N/A
- Revenue Next Year
- VRA $4.90
- IMAB N/A
- P/E Ratio
- VRA N/A
- IMAB N/A
- Revenue Growth
- VRA N/A
- IMAB N/A
- 52 Week Low
- VRA $3.27
- IMAB $0.84
- 52 Week High
- VRA $8.32
- IMAB $2.08
- Technical
- Relative Strength Index (RSI)
- VRA 43.07
- IMAB 55.17
- Support Level
- VRA $3.46
- IMAB $1.00
- Resistance Level
- VRA $4.00
- IMAB $1.20
- Average True Range (ATR)
- VRA 0.21
- IMAB 0.12
- MACD
- VRA 0.07
- IMAB 0.02
- Stochastic Oscillator
- VRA 51.56
- IMAB 40.97
About VRA Vera Bradley Inc.
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the most. most of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).